- Education levels and survival in colorectal cancer: is there really an obvious association?
-
Valiati B, Perez RO, Kotze PG
- KMID: 2504579
- Intest Res.
- 2020 Jul;18(3):247-248.
- doi: 10.5217/ir.2020.00064
-
- CITED
-
- Close
- SHARE
-
- Close
- Endoscopic Postoperative Recurrence Rates in Crohn's Disease in Korea: The Beginning of a New Approach?
-
Kotze PG, Saad-Hossne R, Spinelli A
- KMID: 2174387
- Intest Res.
- 2014 Jul;12(3):258-259.
- doi: 10.5217/ir.2014.12.3.258
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- The old versus the new: which do you keep in postoperative Crohn's disease?
-
Kotze PG, Ma C, Regueiro M, Panaccione R
- KMID: 2417687
- Intest Res.
- 2018 Apr;16(2):319-320.
- doi: 10.5217/ir.2018.16.2.319
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls
-
Kotze PG, Ghosh S, Bemelman W, Panaccione R
- KMID: 2425156
- Intest Res.
- 2017 Apr;15(2):160-165.
- doi: 10.5217/ir.2017.15.2.160
Recent advances in medical and surgical therapy were achieved during the last two decades in the management of Crohn's disease (CD). Anti-tumor necrosis factor (anti-TNF) agents are widely used worldwide.... -
- CITED
-
- Close
- SHARE
-
- Close
- Conventional Versus Biological Therapy for Prevention of Postoperative Endoscopic Recurrence in Patients With Crohn's Disease: an International, Multicenter, and Observational Study
-
Kotze PG, Spinelli A, da Silva R, de Barcelos IF, Teixeira F, Saad-Hossne R, de Albuquerque IC, Olandoski , da Silva Kotze LM, Suzuki Y, Yamada A, Takeuchi K, Sacchi M, Yamamoto T
- KMID: 2174479
- Intest Res.
- 2015 Jul;13(3):259-265.
- doi: 10.5217/ir.2015.13.3.259
BACKGROUND/AIMS: Postoperative endoscopic recurrence (PER) occurs in nearly 80% of patients 1 year after ileocecal resection in patients with Crohn's disease (CD). Biological agents were more effective in reducing the... -
- CITED
-
- Close
- SHARE
-
- Close
- Biological Therapy for the Prevention and Treatment of Postoperative Endoscopic Recurrence in Crohn's Disease: Time for Acceptance?
-
Kotze PG, Saad-Hossne R
- KMID: 2284912
- Intest Res.
- 2013 Oct;11(4):256-260.
- doi: 10.5217/ir.2013.11.4.256
In most patients, postoperative endoscopic recurrence (PER) occurs 1 year after abdominal resection for Crohn's disease (CD). Preventing PER is essential for disease control, as most patients develop further clinical... -
- CITED
-
- Close
- SHARE
-
- Close
- Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn’s disease: a narrative review
-
Miranda EF, Nones RB, Kotze PG
- KMID: 2518681
- Intest Res.
- 2021 Jul;19(3):255-264.
- doi: 10.5217/ir.2020.00029
With the overspread use of measurement of serum levels of anti-tumor necrosis factor (TNF) agents (therapeutic drug monitoring, TDM), new therapeutic strategies have been used in the management of Crohn’s... -
- CITED
-
- Close
- SHARE
-
- Close
- Hypoalbuminemia as a risk factor for thromboembolic events in inflammatory bowel disease inpatients
-
Imbrizi MR, Magro DO, Secundo TD, Cunha-Silva M, Kotze PG, Montes CG, Almeida JR, Cabral VL
- KMID: 2438444
- Intest Res.
- 2019 Jan;17(1):63-69.
- doi: 10.5217/ir.2018.00077
BACKGROUND/AIMS: Inflammatory bowel disease (IBD) are chronic entities characterized by local and systemic inflammation and may be associated with thrombosis. The aim of this study was to identify the prevalence... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of time until elective intestinal resection regarding previous anti-tumor necrosis factor exposure: a Brazilian study on patients with Crohn's disease
-
Kotze PG, Magro DO, Saab B, Saab MP, Pinheiro L, Olandoski , Ayrizono M, Martinez C, Coy CS
- KMID: 2402648
- Intest Res.
- 2018 Jan;16(1):62-68.
- doi: 10.5217/ir.2018.16.1.62
BACKGROUND/AIMS: The use of anti-tumor necrosis factor (anti-TNF) agents seems to reduce surgical rates and delay surgical procedures in prospective trials and population-based studies in the management of Crohn's disease... -
- CITED
-
- Close
- SHARE
-
- Close
- Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn's disease
-
Magro DO, Kotze PG, Martinez C, Camargo MG, Guadagnini D, Calixto AR, Vasques AC, Ayrizono M, Geloneze B, Pareja JC, Saad MJ, Coy CS
- KMID: 2382379
- Intest Res.
- 2017 Jul;15(3):352-357.
- doi: 10.5217/ir.2017.15.3.352
BACKGROUND/AIMS: Lipopolysaccharide (LPS) is a molecule formed by lipids and polysaccharides and is the major cell wall component of gram-negative bacteria. High LPS levels are known to block CD26 expression... -
- CITED
-
- Close
- SHARE
-
- Close
- Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy–Access to Rapid Treatment (iSTART) approach
-
Danese S, Banerjee R, Cummings J, Dotan I, Kotze PG, Leong RW, Paridaens , Peyrin-Biroulet L, Scott G, Assche GV, Wehkamp J, Yamamoto-Furusho JK
- KMID: 2434153
- Intest Res.
- 2018 Oct;16(4):522-528.
- doi: 10.5217/ir.2018.00073
Symptomatic ulcerative colitis (UC) can be a chronic, disabling condition. Flares in disease activity are associated with many of the negative impacts of mild-to-moderate UC. Rapid resolution of flares can... -
- CITED
-
- Close
- SHARE
-
- Close
